- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07947056
A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)
A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
Study Overview
Status
Conditions
Detailed Description
Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Dr PK Bhavani, MBBS., MPH., PGDBEME
- Phone Number: 044 2836 9537
- Email: bhavani.pk@icmr.gov.in
Study Contact Backup
- Name: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Phone Number: 044 2836 9518
- Email: narendra.ng@icmr.gov.in
Study Locations
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, India, 522503
- Recruiting
- All India Institute of Medical Sciences(AIIMS), Mangalagiri
-
Contact:
- Dr S Sathiyanarayanan, MBBS., MD
- Phone Number: 08645 280021
- Email: sathiya@aiimsmangalagiri.edu.in
-
-
Assam
-
Guwahati, Assam, India, 781101
- Active, not recruiting
- All India Institute of Medical Sciences, Guwahati
-
-
Gujarat
-
Rajkot, Gujarat, India, 360001
- Not yet recruiting
- Govt. PDU Medical College
-
Contact:
- Dr Bhoomika Patel, MBBS., MD
- Phone Number: 0281 245 8337
- Email: doctorbhoomika@gmail.com
-
Surat, Gujarat, India, 395001
- Active, not recruiting
- Govt. Medical College and NCH
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400008
- Recruiting
- Grant Govt. Medical College & Sir JJ Group of Hospitals
-
Contact:
- Dr Priti Meshram, MBBS., MD., DNB
- Phone Number: 022 2373 5555
- Email: drpritimeshram@gmail.com
-
Nagpur, Maharashtra, India
- Not yet recruiting
- All India Institute Of Medical Sciences, Nagpur
-
Contact:
- Dr Yogesh Bahurupi, MBBS., MD
- Phone Number: 0712 2352078
- Email: dr.yogeshab@gmail.com
-
-
Meghālaya
-
Shillong, Meghālaya, India, 793018
- Recruiting
- North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
-
Contact:
- Dr Monaliza Lyngdoh, MBBS., MD
- Phone Number: 0364 2538013
- Email: monalizalyngdoh@gmail.com
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, India, 110030
- Not yet recruiting
- National Institute of TB and Respiratory Diseases
-
Contact:
- Dr Jitendra Kumar Saini, MBBS., MD
- Phone Number: 011 2651 3325
- Email: drsaini1973@gmail.com
-
-
Odisha
-
Bhubaneswar, Odisha, India, 751019
- Active, not recruiting
- All India Institute of Medical Sciences (AIIMS), Bhubaneswar
-
Bhubaneswar, Odisha, India, 751001
- Active, not recruiting
- Post Graduate Institute of Medical Education & Research, Capital Hospital
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600031
- Recruiting
- ICMR - National Institute for Research in Tuberculosis
-
Contact:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
- Phone Number: 044 2836 9537
- Email: bhavani.pk@icmr.gov.in
-
Contact:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Phone Number: 044 2836 9518
- Email: narendra.ng@icmr.gov.in
-
Principal Investigator:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
-
Principal Investigator:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
-
Sub-Investigator:
- Dr R Balaji, MBBS., MD.,
-
-
Telangana
-
Hyderabad, Telangana, India, 500038
- Recruiting
- Govt. General and Chest Hospital, Osmania Medical College
-
Contact:
- Dr V Karthik, MBBS., MD
- Phone Number: 04083814421
- Email: vkarthikrao19@gmail.com
-
-
Uttar Pradesh
-
Agra, Uttar Pradesh, India, 282002
- Recruiting
- Sarojini Naidu Medical College
-
Contact:
- Dr Gajendra Vikram Singh, MBBS., MD
- Phone Number: 0562 2260353
- Email: drsinghgv@gmail.com
-
Allahābād, Uttar Pradesh, India, 211002
- Recruiting
- Moti Lal Nehru Medical College
-
Contact:
- Dr Amitabh Das Shukla, MBBS., MD
- Phone Number: 0532 261 3592
- Email: adshukla1977@gmail.com
-
Lucknow, Uttar Pradesh, India, 226003
- Recruiting
- King George Medical University
-
Contact:
- Dr Rajiv Garg, MBBS., MD
- Phone Number: 0522 2255167
- Email: rajivkgmc@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals aged equal or above 14 years.
- Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
- Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
- If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
- Willing to follow the trial procedures
Exclusion Criteria:
-
Body weight less than 30 kg in adults
-
Anti-TB treatment, >14 days for the current illness
-
Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA
-
Patients with serious forms of Extra-pulmonary TB
-
HIV Patients on second line ART regimens.
-
Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities
- ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
- Serum Creatinine >1.2 mg/dl.
-
Pregnant or lactating mothers
-
Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability
-
Patients with h/o of concomitant medications which may interfere with study drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 2H R25 ZE /4 H R10 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Experimental: 2 H R25 ZE/ 4 H R25 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Experimental: 2 H R25 ZE L/2 H R25 E L
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin. |
Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs. |
|
Active Comparator: 2 H R10 ZE /4H R10 E
Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol |
Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
Time Frame: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients with grade 3 or 4 adverse drug reactions.
Time Frame: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
Time Frame: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
Time Frame: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
|
|
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
Time Frame: At 1st Month
|
At 1st Month
|
|
|
The cost effectiveness of different treatment regimens
Time Frame: Through treatment completion, an average of 24 weeks
|
Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB. |
Through treatment completion, an average of 24 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dr PK Bhavani, MBBS., MPH., PGDBEME, ICMR - National Institute for Research in Tuberculosis
- Principal Investigator: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,, ICMR - National Institute for Research in Tuberculosis
Publications and helpful links
General Publications
- Kannabiran BP, Arthanari J, Bhaskar A, Narayanan MKS, Inbaraj LR. Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis. Indian J Med Res. 2025 May;161(5):449-460. doi: 10.25259/IJMR_1673_2024.
- Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. eCollection 2024 Mar.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Infections
- Infections
- Respiratory Tract Diseases
- Lung Diseases
- Gram-Positive Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Tuberculosis, Pulmonary
- Health Care Quality, Access, and Evaluation
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Therapeutics
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Polycyclic Compounds
- Heterocyclic Compounds, 4 or More Rings
- Rifamycins
- Lactams, Macrocyclic
- Macrocyclic Compounds
- Fluoroquinolones
- 4-Quinolones
- Quinolones
- Quinolines
- Ofloxacin
- Epidemiologic Study Characteristics
- Rifampin
- Levofloxacin
- Clinical Protocols
Other Study ID Numbers
- 2025 011
- CTRI/2026/02/102698 (Registry Identifier: CLINICAL TRIALS REGISTRY - INDIA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.